Pacira Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on June 14, 2016, regarding Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.). The filing documents the outcomes of the Company's 2016 Annual Meeting of Stockholders held in New York, New York.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting results rather than financial performance.
Material Changes and Corporate Actions
- Stock Incentive Plan Amendment: Stockholders approved the Amended and Restated 2011 Stock Incentive Plan. Key changes include an increase of 4,000,000 newly reserved shares authorized for grant and the addition of a limit on aggregate annual compensation for non-employee directors.
- Director Elections: Three Class II directors were elected to serve until the 2019 Annual Meeting: Paul Hastings, John Longenecker, and Andreas Wicki.
- Accounting Firm Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- Executive Compensation: Stockholders cast an advisory vote to approve the compensation of the Company's named executive officers.
Voting Results
| Proposal | For | Against | Abstain/Withheld | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors | 29,040,511 - 29,333,066 | N/A | 122,556 - 415,111 | 3,932,809 |
| Ratify KPMG LLP | 33,321,066 | 63,539 | 3,826 | N/A |
| Executive Compensation (Say-on-Pay) | 29,295,692 | 141,198 | 18,732 | 3,932,809 |
| Amended 2011 Stock Plan | 19,986,074 | 9,460,843 | 8,705 | 3,932,809 |
Outlook, Risks, and Contingencies
The filing text does not provide specific guidance, outlook, management commentary on future operations, or new risk factors. The document serves as a record of the completed Annual Meeting and the immediate effectiveness of the amended stock plan.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to assess the dilution impact of the 4,000,000 newly reserved shares.
- Review the full text of the Amended and Restated 2011 Stock Incentive Plan (Exhibit 10.1) for specific terms regarding the new director compensation limits.
- Note the significant number of broker non-votes (3,932,809) on director elections and the stock plan, indicating a large portion of shares were held in street name without voting instructions on these specific matters.
- Confirm the re-election of the Class II directors and their tenure through 2019.